UI-102 for Cancer

This trial tests a new cancer treatment called UI-102. Researchers aim to determine if UI-102 is safe and effective for individuals with advanced cancer that has spread or cannot be surgically removed. The study consists of two parts: one administering UI-102 alone and another combining it with standard cancer treatments. Suitable participants have advanced cancer that hasn't responded to conventional treatments. As a Phase 1 and Phase 2 trial, this research focuses on understanding how UI-102 works in people and measuring its effectiveness in an initial group, offering participants the opportunity to be among the first to benefit from this innovative treatment.

The trial information does not specify if you need to stop taking your current medications. However, if you are on immunosuppressive treatment, you may not be eligible to participate.

Research shows that UI-102, a new cancer treatment, is undergoing tests to determine its safety and effectiveness in people. Early studies suggest it might offer a safer option for treating "cold tumors," which do not respond well to the body's immune system.

Researchers are testing UI-102 both alone and in combination with other common cancer treatments. So far, the safety results align with expectations based on similar treatments. While risks always exist, no unexpected severe side effects have appeared in the studies so far.

Researchers are excited about UI-102 for cancer treatment because it offers a novel approach compared to traditional chemotherapy and immunotherapy options. Unlike these existing treatments, UI-102 is an experimental drug that can be administered both as a monotherapy and in combination with other standard-of-care agents, potentially enhancing its effectiveness. A key feature of UI-102 is its innovative delivery via intravenous infusion, which is designed to maximize the drug's efficacy in targeting locally advanced and metastatic solid tumors. This dual approach allows for dose escalation and optimization, aiming to improve outcomes while potentially reducing side effects.

Studies have shown that UI-102, a new cancer treatment, has promising effects. In this trial, participants may receive UI-102 as a monotherapy, which has demonstrated strong anti-cancer activity across various cancer types. Some studies found that more than half of the patients did not experience cancer progression for at least six months. Alternatively, participants may receive UI-102 combined with other standard treatments, which has yielded even better results, with up to 70% of patients responding positively. This suggests that UI-102 could help slow tumor growth and improve treatment outcomes for patients with advanced solid tumors.¹³⁶⁷⁸